Company: SYRA
Filing Date: 2025-01-24
Form Type: S-3
Source: 0001493152-25-003630
Chunk: 4

Company: Syra Health Corp
Filing Date: 2025-01-24
Form: S-3
Chunk 4
---
                                 | 10 |
| DESCRIPTION OF CAPITAL STOCK                    | 10 |
| DESCRIPTION OF DEBT SECURITIES                  | 14 |
| DESCRIPTION OF WARRANTS                         | 21 |
| DESCRIPTION OF UNITS                            | 23 |
| LEGAL OWNERSHIP OF SECURITIES                   | 24 |
| PLAN OF DISTRIBUTION                            | 27 |
| LEGAL MATTERS                                   | 30 |
| EXPERTS                                         | 30 |
| WHERE YOU CAN FIND MORE INFORMATION             | 30 |
| INCORPORATION OF DOCUMENTS BY REFERENCE         | 31 |

| i |

<div align='center'>ABOUT THIS PROSPECTUS</div>

This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission (“SEC”) using a “shelf” registration process. Under this shelf registration statement, we may sell from time to time in one or more offerings of Class A Common Stock and Preferred Stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or as units comprised of a combination of one or more of the other securities in one or more offerings up to a total dollar amount of $75 million. This prospectus provides you with a general description of the securities we may offer. Each time we sell any type or series of securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of that offering.

This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits. We may add, update or change, in a prospectus supplement or free writing prospectus, any of the information contained in this prospectus or in the documents we have incorporated by reference into this prospectus. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. This prospectus, together with the applicable prospectus supplement, any related free writing prospectus and the documents incorporated by reference into this prospectus and the applicable prospectus supplement, will include all material information relating to the applicable offering. You should carefully read both this prospectus and the applicable prospectus supplement and any related free writing prospectus, together with the additional information described under “ Where You Can Find More Information,” before buying any of the securities being offered.

We have not authorized any dealer, agent or other person to give any information or to